In relation to cancer cell growth inhibition, the superior potency of sapanisertib/sapanisertib plus serabelisib versus other inhibitors correlated with the ability to inhibit 4E-BP1 (rather than S6) phosphorylation at clinically relevant concentrations. Here, EIF4EBP1 is linked to cancer.